Pirtobrutinib in relapsed or refractory mantle cell lymphoma: a profile of its use

Pirtobrutinib (Jaypirca^®), an oral, small molecule, non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, is a promising new treatment option for patients with relapsed or refractory mantle cell lymphoma (MCL), including those who have received a BTK inhibitor. In the multicentre, open-label, phase 1/2 BRUIN trial, pirtobrutinib demonstrated meaningful response rates and durable efficacy in patients with heavily pretreated (including with a covalent BTK inhibitor) relapsed or refractory MCL. Pirtobrutinib had a manageable tolerability profile, with most treatment-related adverse events being mild to moderate in severity. Longer term, the tolerability profile of pirtobrutinib revealed no new safety signals.